Dirui Industrial Co., Ltd. Class A

Dirui Industrial Co., Ltd. Class A

SSZSE:300396
6.94
CNY
-0.07
(-1.00%)
-0.64EPS
1.93BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.24
2.16
2.07
2.75
3.14
3.38
3.68
3.4
3.28
4.47
4.12
3.6
2.95
3.56
Basic EPS, GAAP
0.45
0.45
0.39
0.45
0.61
0.72
0.85
0.97
0.76
0.96
0.59
0.24
-0.9
-0.64
Free Cash Flow per Basic Share
0.3
0.31
0.21
0.57
0.66
0.78
1
0.83
0.55
0.11
0.71
-1.16
0.06
- -
Dividend per Share
0.15
- -
0.11
0.15
0.13
0.21
0.29
0.51
0.51
0.4
0.52
0.54
0.3
0.04
Book Value per Share
1.93
3.33
3.61
3.96
4.48
5
5.52
5.99
6.8
6.98
7
6.8
5.64
5.58
Tangible Book Value per Share
1.88
3.3
0.95
1.38
1.94
2.49
3.07
5.63
6.43
6.62
6.66
6.45
5.38
5.34
Basic Weighted Avg Shares
208
225
275
276
276
276
274
275
276
273
270
271
273
272
Sales/Revenue/Turnover
464
486
567
759
868
933
1,009
937
906
1,220
1,112
977
807
969
Operating Margin (%)
21.77
19.06
18.41
20.51
26.67
28.52
29.66
25.19
22.01
22.01
11.66
7.15
-10.83
7.65
Depreciation Expense
14
17
30
57
64
66
69
56
35
35
41
41
47
- -
Net Income, GAAP
94
101
108
125
167
198
232
267
210
262
159
65
-246
-174
Effective Tax Rate (%)
11.62
11.64
12.38
13.03
13.03
12.93
11.88
8.95
8.37
10.16
0.06
5.46
- -
- -
Profit Margin (%)
20.16
20.84
19.09
16.49
19.29
21.18
22.99
28.5
23.18
21.46
14.32
6.67
-30.48
-18
Working Capital
265
768
488
419
372
517
702
856
867
922
696
956
765
657
LT Debt
- -
5
155
85
- -
- -
- -
- -
1
51
4
318
245
92
Total Equity
399
920
1,286
1,376
1,414
1,562
1,735
1,655
1,876
1,920
1,923
1,856
1,537
1,521
Return on Invested Capital (%)
20.96
12.53
8.01
8.3
12.66
14.73
15.33
15.52
10.96
12.17
7.09
2.79
- -
- -
Return on Capital (%)
24.59
15.32
7.83
6.42
8.26
10.09
11.16
13.98
11.16
12.42
7.95
4.64
- -
- -
Return on Common Equity (%)
25.47
15.37
11.3
11.98
14.38
15.11
15.96
16.8
11.89
13.79
8.29
3.45
-14.5
-10.03

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
323
386
377
LT Borrowings
45
81
90
LT Finance Leases
4
4
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
273
273
273
Market Capitalization
3,182
1,696
1,931

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,580
1,561
1,472
Cash, Cash Equivalents & STI
386
504
520
Accounts Receivable, Net
180
193
181
Inventories
551
534
494
Total Current Liabilities
1,003
900
816
Payables & Accruals
- -
- -
- -
ST Debt
323
386
377
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.19%
-0.96%
-17.18%
Free Cash Flow
25.64%
7.42%
-105.12%
Net Income, GAAP
-47.26%
-114.49%
-477.53%
Sales/Revenue/Turnover
4.96%
-1.41%
-17.41%
Total Cash Common Dividend
16.1%
-6.7%
-43.97%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
663
216
297
-198
977
2025
182
168
- -
338
807
2026
178
231
222
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.45
0.16
0.1
-0.47
0.24
2025
0.06
-0.16
- -
-0.58
-0.9
2026
- -
0.03
-0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.51
0.01
0.01
0.54
2025
0.01
0.27
- -
0.01
0.3
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Tao Lang
Full Time Employees
1,569
Sector
Health technology
Industry
Medical specialties
Address
No. 3333, Yiju Road Changchun JI China 130103
IPO Date
Sep 10, 2014
Business
Dirui Industrial Co., Ltd. (300396.SZ) engages in the research, development, production, and sale of in-vitro diagnostic instruments, reagents, and test strips primarily in China, with exports to Russia, Latin America, Southeast Asia, the Middle East, and Africa; its core products encompass urine analysis systems including the FUS-2000 hybrid urine dry chemistry and flow cytometry sediment analyzer and H-800 fully automated analyzer, biochemical analysis such as the CS-800 high-speed clinical chemistry analyzer, chemiluminescence immunoassay, gynecological secretion analysis, blood cell and hematology analysis with BF series analyzers, coagulation analysis, integrated laboratory solutions, veterinary diagnostics, molecular diagnostics, and SARS-CoV-2 testing products. Founded in 1992 and headquartered in Changchun, Jilin Province, the company operates as a high-tech enterprise controlled by China Resources Industrial Funds and serves medical institutions across domestic and international markets with a workforce of approximately 1,821 employees. Recent developments include the renewal of its medical device production license, ongoing refinements to production through lean manufacturing and modularization initiatives as outlined in its 2025 half-year report, active participation in global exhibitions such as Medlab Middle East 2024 to showcase lab automation technologies, and strategic adjustments amid China's equipment update policies under the "China Manufacturing 2025" framework to enhance inventory standardization, domestic sourcing, and supplier synergies.